136 related articles for article (PubMed ID: 18698001)
21. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
Marshall CA; Brodnik ZD; Mortensen OV; Reith MEA; Shumsky JS; Waterhouse BD; España RA; Kortagere S
Neuropharmacology; 2019 Apr; 148():178-188. PubMed ID: 30633928
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Highper, an ENU-induced mouse mutant with abnormal psychostimulant and stress responses.
Eisener-Dorman AF; Bailey JS; Grabowski-Boase L; Huitron-Resendiz S; Roberts AJ; Wiltshire T; Tarantino LM
Psychopharmacology (Berl); 2013 Jan; 225(2):407-19. PubMed ID: 22948668
[TBL] [Abstract][Full Text] [Related]
23. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.
Verrico CD; Lynch L; Fahey MA; Fryer AK; Miller GM; Madras BK
J Psychopharmacol; 2008 Mar; 22(2):187-202. PubMed ID: 18308800
[TBL] [Abstract][Full Text] [Related]
24. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
25. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
[TBL] [Abstract][Full Text] [Related]
26. Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.
Tilleman H; Kofman O; Nashelsky L; Livneh U; Roz N; Sillaber I; Biegon A; Rehavi M; Brodski C
Neuroscience; 2009 Nov; 163(4):1012-23. PubMed ID: 19635527
[TBL] [Abstract][Full Text] [Related]
27. Animal model of methylphenidate's long-term memory-enhancing effects.
Carmack SA; Howell KK; Rasaei K; Reas ET; Anagnostaras SG
Learn Mem; 2014 Jan; 21(2):82-9. PubMed ID: 24434869
[TBL] [Abstract][Full Text] [Related]
28. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions.
Perona MT; Waters S; Hall FS; Sora I; Lesch KP; Murphy DL; Caron M; Uhl GR
Behav Pharmacol; 2008 Sep; 19(5-6):566-74. PubMed ID: 18690111
[TBL] [Abstract][Full Text] [Related]
29. Binding of bromine-substituted analogs of methylphenidate to monoamine transporters.
Pan D; Gatley SJ; Dewey SL; Chen R; Alexoff DA; Ding YS; Fowler JS
Eur J Pharmacol; 1994 Oct; 264(2):177-82. PubMed ID: 7851480
[TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
[TBL] [Abstract][Full Text] [Related]
31. Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice.
Weiss S; Tzavara ET; Davis RJ; Nomikos GG; Michael McIntosh J; Giros B; Martres MP
Neuropharmacology; 2007 Jun; 52(7):1496-508. PubMed ID: 17433376
[TBL] [Abstract][Full Text] [Related]
32. Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.
Gross JD; Kaski SW; Schroer AB; Wix KA; Siderovski DP; Setola V
J Psychopharmacol; 2018 Feb; 32(2):191-203. PubMed ID: 29364035
[TBL] [Abstract][Full Text] [Related]
33. Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.
Bradshaw SE; Agster KL; Waterhouse BD; McGaughy JA
Brain Res; 2016 Jun; 1641(Pt B):245-57. PubMed ID: 26774596
[TBL] [Abstract][Full Text] [Related]
34. Flurazepam effects on methylphenidate-induced stereotyped behavior.
Risch C; Kripke D; Janowsky D
Psychopharmacology (Berl); 1980; 70(1):79-82. PubMed ID: 6775340
[TBL] [Abstract][Full Text] [Related]
35. Functional mutations in mouse norepinephrine transporter reduce sensitivity to cocaine inhibition.
Wei H; Hill ER; Gu HH
Neuropharmacology; 2009 Feb; 56(2):399-404. PubMed ID: 18824182
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical abatement of striatal dopaminergic transmission by cocaine and methylphenidate.
Federici M; Latagliata EC; Ledonne A; Rizzo FR; Feligioni M; Sulzer D; Dunn M; Sames D; Gu H; Nisticò R; Puglisi-Allegra S; Mercuri NB
J Biol Chem; 2014 Jan; 289(1):264-74. PubMed ID: 24280216
[TBL] [Abstract][Full Text] [Related]
37. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.
Volkow ND; Fowler JS; Wang GJ; Ding YS; Gatley SJ
Eur Neuropsychopharmacol; 2002 Dec; 12(6):557-66. PubMed ID: 12468018
[TBL] [Abstract][Full Text] [Related]
38. A Role for p38 Mitogen-activated Protein Kinase-mediated Threonine 30-dependent Norepinephrine Transporter Regulation in Cocaine Sensitization and Conditioned Place Preference.
Mannangatti P; NarasimhaNaidu K; Damaj MI; Ramamoorthy S; Jayanthi LD
J Biol Chem; 2015 Apr; 290(17):10814-27. PubMed ID: 25724654
[TBL] [Abstract][Full Text] [Related]
39. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Hitzemann R; Pappas N
Am J Psychiatry; 1998 Oct; 155(10):1325-31. PubMed ID: 9766762
[TBL] [Abstract][Full Text] [Related]
40. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.
Morón JA; Brockington A; Wise RA; Rocha BA; Hope BT
J Neurosci; 2002 Jan; 22(2):389-95. PubMed ID: 11784783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
